From the Cancer Imaging Program, National Cancer Institute, National Institutes of Health, 9609 Medical Center Dr, Room 4W216, Rockville, MD 20850.
Radiol Imaging Cancer. 2021 May;3(3):e200052. doi: 10.1148/rycan.2021200052.
Nanoparticle (NP) imaging applications have the potential to improve cancer diagnostics, therapeutics, and treatment management. In biomedical research and clinical practice, NPs can serve as labels or labeled carriers for monitoring drug delivery or serve as imaging agents for enhanced imaging contrast, as well as providing improved signal sensitivity and specificity for in vivo imaging of molecular and cellular processes. These qualities offer exciting opportunities for NP-based imaging agents to address current limitations in oncologic imaging. Despite substantial advancements in NP design and development, very few NP-based imaging agents have translated into clinics within the past 5 years. This review highlights some promising NP-enabled imaging techniques and their potential to address current clinical cancer imaging limitations. Although most examples provided herein are from the preclinical space, discussed imaging solutions could offer unique in vivo tools to solve biologic questions, improve cancer treatment effectiveness, and inspire clinical translation innovation to improve patient care. : Molecular Imaging-Cancer, Molecular Imaging-Nanoparticles, Molecular Imaging-Optical Imaging, Metastases, Oncology, Surgery, Treatment Effects.
纳米颗粒（NP）成像应用具有改善癌症诊断、治疗和治疗管理的潜力。在生物医学研究和临床实践中， NPs 可以作为药物输送的标记物或标记载体，也可以作为成像剂，以增强成像对比度，并为分子和细胞过程的体内成像提供更高的信号灵敏度和特异性。这些特性为基于 NP 的成像剂提供了令人兴奋的机会，以解决肿瘤学成像中的当前限制。尽管在 NP 的设计和开发方面取得了重大进展，但在过去 5 年内，只有极少数基于 NP 的成像剂转化为临床应用。本综述强调了一些有前途的基于 NP 的成像技术及其解决当前临床癌症成像限制的潜力。尽管本文提供的大多数示例都来自临床前领域，但所讨论的成像解决方案可以提供独特的体内工具，以解决生物学问题、提高癌症治疗效果，并激发临床转化创新，以改善患者护理。：癌症分子成像、纳米粒子分子成像、光学成像分子成像、转移、肿瘤学、手术、治疗效果。
